“The Most Anticipated Trials at ESC 2025”
“The Most Anticipated Trials at ESC 2025”
Summary:
1. ESC Congress 2025 Overview
• ESC 2025 will be held in Madrid, Spain (Aug 29 – Sept 1).
• Features 38 sessions, including 10 Hot Line and 28 late-breaking science sessions.
• Focus: New treatments, global health issues, and redefining guidelines.
2. Focus on Long-Term Therapy Reassessment
• REBOOT-CNIC & BETAMI-DANBLOCK:
Reevaluate long-term beta-blockers after heart attack, especially in patients with preserved ejection fraction.
• Goal: Reduce drug burden and costs.
3. Antiplatelet/Anticoagulant Simplification
• Trials: NEO-MINDSET, TARGET FIRST, DUAL-ACS, ALONE-AF
• Explore early withdrawal of aspirin or OACs to reduce bleeding and simplify care.
4. Global Health Highlight: Chagas Cardiomyopathy
• PARACHUTE-HF Trial:
Tests sacubitril/valsartan vs enalapril in Latin American patients.
• May lead to first guideline-based treatment for this neglected disease.
5. New Hypertension Therapies
• BaxHTN: Tests new aldosterone synthase inhibitor.
• KARDIA-3: Tests zilebesiran, a twice-yearly siRNA therapy for BP control.
• siRNA could revolutionize hypertension treatment adherence.
6. Heart Failure Breakthroughs
• DAPA ACT HF-TIMI 68:
Starts SGLT2 inhibitors during hospitalization for acute HF.
• VICTOR/VICTORIA: Tests vericiguat as a daily option for chronic HF.
7. Hypertrophic Cardiomyopathy (HCM)
• ODYSSEY-HCM & MAPLE-HCM:
May shift treatment toward oral myosin inhibitors (mavacamten, aficamten), reducing need for surgery.
⸻
📌 Quote from Prof. Tomasz Guzik:
“These trials may change daily practice and guidelines — from how we treat heart attacks to managing hypertension and rare heart diseases.”
